PIR and renal cell carcinoma: This approach results in lower immunogenicity, excellent biocompatibility, prolonged in vivo circulation time, and outstanding target specificity.[28, 29, 72, 73] Here, we utilized renal cancer cell membrane‐coated nanoparticles to target the delivery of piR‐RCC in orthotopic kidney tumor model, offering a translational avenue for piRNA‐based gene therapy (Figure 8).